Heightened COVID-19 Mortality in People With Severe Mental Illness Persists After Vaccination: A Cohort Study of Greater Manchester Residents.

Humans Depressive Disorder, Major / epidemiology Cohort Studies COVID-19 / prevention & control Mental Disorders / epidemiology Logistic Models Vaccination

Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
15 03 2023
Historique:
pubmed: 28 8 2022
medline: 21 3 2023
entrez: 27 8 2022
Statut: ppublish

Résumé

Previous studies show that people with severe mental illness (SMI) are at higher risk of COVID-19 mortality, however limited evidence exists regarding risk postvaccination. We investigated COVID-19 mortality among people with schizophrenia and other SMIs before, during and after the UK vaccine roll-out. Using the Greater Manchester (GM) Care Record to access routinely collected health data linked with death records, we plotted COVID-19 mortality rates over time in GM residents with schizophrenia/psychosis, bipolar disorder (BD), and/or recurrent major depressive disorder (MDD) from February 2020 to September 2021. Multivariable logistic regression was used to compare mortality risk (risk ratios; RRs) between people with SMI (N = 193 435) and age-sex matched controls (N = 773 734), adjusted for sociodemographic factors, preexisting comorbidities, and vaccination status. Mortality risks were significantly higher among people with SMI compared with matched controls, particularly among people with schizophrenia/psychosis (RR 3.18, CI 2.94-3.44) and/or BD (RR 2.69, CI 2.16-3.34). In adjusted models, the relative risk of COVID-19 mortality decreased, though remained significantly higher than matched controls for people with schizophrenia (RR 1.61, CI 1.45-1.79) and BD (RR 1.92, CI 1.47-2.50), but not recurrent MDD (RR 1.08, CI 0.99-1.17). People with SMI continued to show higher mortality rate ratios relative to controls throughout 2021, during vaccination roll-out. People with SMI, notably schizophrenia and BD, were at greater risk of COVID-19 mortality compared to matched controls. Despite population vaccination efforts that have prioritized people with SMI, disparities still remain in COVID-19 mortality for people with SMI.

Sections du résumé

BACKGROUND AND HYPOTHESIS
Previous studies show that people with severe mental illness (SMI) are at higher risk of COVID-19 mortality, however limited evidence exists regarding risk postvaccination. We investigated COVID-19 mortality among people with schizophrenia and other SMIs before, during and after the UK vaccine roll-out.
STUDY DESIGN
Using the Greater Manchester (GM) Care Record to access routinely collected health data linked with death records, we plotted COVID-19 mortality rates over time in GM residents with schizophrenia/psychosis, bipolar disorder (BD), and/or recurrent major depressive disorder (MDD) from February 2020 to September 2021. Multivariable logistic regression was used to compare mortality risk (risk ratios; RRs) between people with SMI (N = 193 435) and age-sex matched controls (N = 773 734), adjusted for sociodemographic factors, preexisting comorbidities, and vaccination status.
STUDY RESULTS
Mortality risks were significantly higher among people with SMI compared with matched controls, particularly among people with schizophrenia/psychosis (RR 3.18, CI 2.94-3.44) and/or BD (RR 2.69, CI 2.16-3.34). In adjusted models, the relative risk of COVID-19 mortality decreased, though remained significantly higher than matched controls for people with schizophrenia (RR 1.61, CI 1.45-1.79) and BD (RR 1.92, CI 1.47-2.50), but not recurrent MDD (RR 1.08, CI 0.99-1.17). People with SMI continued to show higher mortality rate ratios relative to controls throughout 2021, during vaccination roll-out.
CONCLUSIONS
People with SMI, notably schizophrenia and BD, were at greater risk of COVID-19 mortality compared to matched controls. Despite population vaccination efforts that have prioritized people with SMI, disparities still remain in COVID-19 mortality for people with SMI.

Identifiants

DOI: 10.1093/schbul/sbac118 PMID: 36029257 PMC: PMC9452124
pubmed: 36029257
pii: 6677964
doi: 10.1093/schbul/sbac118
pmc: PMC9452124
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

275-284

Subventions

Organisme : Medical Research Council
ID : MR/T021780/1
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Auteurs

Lamiece Hassan (L)

Division of Psychology and Mental Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.
ORCID: 0000-0002-5888-422X

Chelsea Sawyer (C)

Division of Psychology and Mental Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.

Niels Peek (N)

Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, The University of Manchester, M13 9PL, UK.
NIHR Greater Manchester Patient Safety Translational Research Centre, The University of Manchester, Manchester, UK.
Manchester Academic Health Science Centre, National Institute for Health Research Manchester Biomedical Research Centre, The University of Manchester, Manchester, M13 9PL, UK.
ORCID: 0000-0002-6393-9969

Karina Lovell (K)

Division of Nursing, Midwifery and Social Work, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.

Andre F Carvalho (AF)

IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, Victoria, Australia.

Marco Solmi (M)

Psychiatry Department, University of Ottawa, Ottawa, ON, Canada.
The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
Clinical Epidemiology Program, Ottawa Hospital Research Institute (OHRI), University of Ottawa, Ottawa, ON, Canada.
ORCID: 0000-0003-4877-7233

George Tilston (G)

Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, The University of Manchester, M13 9PL, UK.
Manchester Academic Health Science Centre, National Institute for Health Research Manchester Biomedical Research Centre, The University of Manchester, Manchester, M13 9PL, UK.

Matthew Sperrin (M)

Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, The University of Manchester, M13 9PL, UK.

Joseph Firth (J)

Division of Psychology and Mental Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.
Greater Manchester Mental Health NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Heightened COVID-19 Mortality in People With...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif majeur › Heightened COVID-19 Mortality in People With...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Heightened COVID-19 Mortality in People With...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Heightened COVID-19 Mortality in People With...
questionsmedicales.fr › Troubles mentaux › Heightened COVID-19 Mortality in People With...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de régression › Modèles logistiques › Heightened COVID-19 Mortality in People With...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Heightened COVID-19 Mortality in People With...